# US 6,727,253 B2 · Treatment of accidental extravasation of anthracyclines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,253 B2
- Document ID: US6727253B2
- Status: Granted
- Kind: B2
- Application number: 09/893,521
- Filed: 2001-06-29
- Published: 2002-07-25
- Granted: 2004-04-27
- Earliest claimed: 1999-03-12
- Assignees: Antianthra APS
- Inventors: Seppo W. Langer; Peter B. Jensen; Maxwell Sehested
- Web page: https://patentgrep.com/patent/US6727253B2

## CPC

- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 35/00: Antineoplastic agents
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method for pharmacological treatment of accidental extravasation of topoisomerase II poisons, such as anthracyclines. In particular, the invention relates to the use of a topo II catalytic inhibitor, such as the bisdioxopiperazine ICRF-187, for the treatment of an accidental extravasation of a topoisomerase II poison. A method for treatment of such extravasation of a topoisomerase poison such as the anthracyclines, daunorubicin, doxorubicin, epirubicin, or idarubicin is disclosed.

## Claims

### Claim 1

A method for preventing or treating local tissue damage due to accidental extravasation of a cytotoxic topoisomerase II poison in a patient receiving treatment with the topoisomerase II poison, comprising administration of a topo II catalytic inhibitor to the patient in need thereof,
where said topo II catalytic inhibitor is a bisdioxopiperazine.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the bisdioxopiperazine ICRF-187, (dexrazoxane).

### Claim 3 (depends on 1)

A method according to claim 1 wherein the administration of the topo II catalytic inhibitor is by local administration to the tissue affected by the extravasation of the topoisomerase II poison.

### Claim 4 (depends on 1)

A method according to claim 1 wherein the administration of the topo II catalytic inhibitor is by systemic administration to the tissue affected by the extravasation of the topoisomerase II poison.

### Claim 5 (depends on 1)

A method according to claim 1 wherein the topoisomerase II poison is selected from the group consisting of etoposide, etoposide phosphate, teniposide, mitoxantrone, and m-AMSA.

### Claim 6 (depends on 1)

A method according to claim 1 wherein the topo II catalytic inhibitor is administered after the treatment with the topoisomerase II poison.

### Claim 7 (depends on 1)

A method according to claim 1 wherein the topo II catalytic inhibitor is administered after treatment with the topoisomerase II poison and while the tissue contains topoisomerase II poison or its active metabolites.

### Claim 8 (depends on 3)

A method according to claim 3 wherein the topo II inhibitor is administered after the occurrence of accidental extravasation of said topoisomerase II poison.

### Claim 9 (depends on 8)

A method according to claim 8 wherein the topo II inhibitor is administered after first occurrence of pain, erythema or swelling due to accidental extravasation of said topoisomerase II poison.

### Claim 10 (depends on 7)

A method according to claim 7 wherein the topo II inhibitor is administered more than 24 hours after administration of the topoisomerase II poison.

### Claim 11 (depends on 7)

A method according to claim 7 wherein the topo II inhibitor is first administered more than 24 hours after administration of the topoisomerase II poison.

### Claim 12 (depends on 1)

A method according to claim 1 wherein the topo II catalytic inhibitor is administered substantially concomitantly with the administration of the topoisomerase II poison.

### Claim 13 (depends on 1)

A method according to claim 1, wherein the topo II catalytic inhibitor is administered in the period within 3 weeks after the administration of the topo II poison.

### Claim 14 (depends on 1)

A method according to claim 1, wherein the topo II catalytic inhibitor is administered in the period within 18 hours after the administration of the topo II poison.

### Claim 15 (depends on 1)

A method according to claim 1, wherein the topo II catalytic inhibitor is administered with at least 2 repeated dosages.

### Claim 16 (depends on 15)

A method according to claim 15, wherein the repeated dosages are administered with an interval of 1 to 3 days from the first dosage.

### Claim 17 (depends on 15)

A method according to claim 15, wherein the repeated dosages are administered with an interval of at the most 24 hours from the first dosage of the topo II catalytic inhibitor.

### Claim 18 (depends on 1)

A method according to claim 1, wherein the II catalytic inhibitor is administered with at least 3 repeated dosages.

### Claim 19 (depends on 18)

A mehtod according to claim 18, wherein the topo II catalytic inhibitor is administered with at least 4 repeated dosages.

### Claim 20 (depends on 1)

A method according to claim 1, wherein the topo II catalytic inhibitor is administered within 12 hours of recognition or suspicion of extravasation of the topoisomerase II poison.

### Claim 21 (depends on 1)

A method according to claim 1, wherein the topo II catalytic inhibitor is administered within 12 hours of administration of the topoisomerase II poison.

### Claim 22 (depends on 1)

A method according to claim 1, wherein the topoisomerase II poison is an anthracycline.

### Claim 23 (depends on 22)

A method according to claim 22 wherein the topoisomerase II poison is selected from the group consisting of daunorubicin, doxorubicin, idarubicin, and epirubicin.

### Claim 24 (depends on 1)

A method according to claim 1, wherein the topoisomerase II poison is daunorubicin.

### Claim 25 (depends on 1)

A method according to claim 1, wherein the topoisomerase II poison is doxorubicin.

### Claim 26 (depends on 1)

A method according to claim 1, wherein the topoisomerase II poison is idarubicin.

### Claim 27 (depends on 1)

A method according to claim 1, wherein the topoisomerase II poison is epirubicin.

### Claim 28 (depends on 1)

A method according to claim 1 wherein the topo II inhibitor is administered in an amount sufficient to be present in the tissue to be prevented from or treated for tissue damage.

### Claim 29 (depends on 1)

A method according to claim 1, wherein the topo II catalytic inhibitor is administered within 6 hours of administration of the topoisomerase II poison.

### Claim 30 (depends on 1)

A method according to claim 1, wherein the topo II catalytic inhibitor is administered within 4 hours of administration of the topoisomerase II poison.

### Claim 31 (depends on 1)

A method according to claim 1, wherein the topo II catalytic inhibitor is administered within 2 hours of administration of the topoisomerase II poison.
